372 related articles for article (PubMed ID: 26323666)
1. Linking RAGE and Nox in diabetic micro- and macrovascular complications.
Koulis C; Watson AMD; Gray SP; Jandeleit-Dahm KA
Diabetes Metab; 2015 Sep; 41(4):272-281. PubMed ID: 26323666
[TBL] [Abstract][Full Text] [Related]
2. RAGE-Aptamer Blocks the Development and Progression of Experimental Diabetic Nephropathy.
Matsui T; Higashimoto Y; Nishino Y; Nakamura N; Fukami K; Yamagishi SI
Diabetes; 2017 Jun; 66(6):1683-1695. PubMed ID: 28385802
[TBL] [Abstract][Full Text] [Related]
3. The pathobiology of diabetic vascular complications--cardiovascular and kidney disease.
Gray SP; Jandeleit-Dahm K
J Mol Med (Berl); 2014 May; 92(5):441-52. PubMed ID: 24687627
[TBL] [Abstract][Full Text] [Related]
4. Receptor for advanced glycation end products (RAGE): a novel therapeutic target for diabetic vascular complication.
Yamagishi S; Nakamura K; Matsui T; Noda Y; Imaizumi T
Curr Pharm Des; 2008; 14(5):487-95. PubMed ID: 18289075
[TBL] [Abstract][Full Text] [Related]
5. Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes.
Soro-Paavonen A; Watson AM; Li J; Paavonen K; Koitka A; Calkin AC; Barit D; Coughlan MT; Drew BG; Lancaster GI; Thomas M; Forbes JM; Nawroth PP; Bierhaus A; Cooper ME; Jandeleit-Dahm KA
Diabetes; 2008 Sep; 57(9):2461-9. PubMed ID: 18511846
[TBL] [Abstract][Full Text] [Related]
6. AGE-RAGE axis blockade in diabetic nephropathy: Current status and future directions.
Sanajou D; Ghorbani Haghjo A; Argani H; Aslani S
Eur J Pharmacol; 2018 Aug; 833():158-164. PubMed ID: 29883668
[TBL] [Abstract][Full Text] [Related]
7. AKF-PD alleviates diabetic nephropathy via blocking the RAGE/AGEs/NOX and PKC/NOX Pathways.
Qin J; Peng Z; Yuan Q; Li Q; Peng Y; Wen R; Hu Z; Liu J; Xia X; Deng H; Xiong X; Hu J; Tao L
Sci Rep; 2019 Mar; 9(1):4407. PubMed ID: 30867431
[TBL] [Abstract][Full Text] [Related]
8. Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications.
Yamagishi S; Nakamura K; Matsui T; Ueda S; Fukami K; Okuda S
Expert Opin Investig Drugs; 2008 Jul; 17(7):983-96. PubMed ID: 18549336
[TBL] [Abstract][Full Text] [Related]
9. Regulation of RAGE for attenuating progression of diabetic vascular complications.
Win MT; Yamamoto Y; Munesue S; Saito H; Han D; Motoyoshi S; Kamal T; Ohara T; Watanabe T; Yamamoto H
Exp Diabetes Res; 2012; 2012():894605. PubMed ID: 22110482
[TBL] [Abstract][Full Text] [Related]
10. Effect of irreversibly glycated LDL in human vascular smooth muscle cells: lipid loading, oxidative and inflammatory stress.
Sima AV; Botez GM; Stancu CS; Manea A; Raicu M; Simionescu M
J Cell Mol Med; 2010 Dec; 14(12):2790-802. PubMed ID: 19818091
[TBL] [Abstract][Full Text] [Related]
11. Involvement of the toxic AGEs (TAGE)-RAGE system in the pathogenesis of diabetic vascular complications: a novel therapeutic strategy.
Takeuchi M; Takino J; Yamagishi S
Curr Drug Targets; 2010 Nov; 11(11):1468-82. PubMed ID: 20583971
[TBL] [Abstract][Full Text] [Related]
12. RAGE: a novel target for drug intervention in diabetic vascular disease.
Hudson BI; Schmidt AM
Pharm Res; 2004 Jul; 21(7):1079-86. PubMed ID: 15290845
[TBL] [Abstract][Full Text] [Related]
13. NADPH oxidase: A membrane-bound enzyme and its inhibitors in diabetic complications.
Laddha AP; Kulkarni YA
Eur J Pharmacol; 2020 Aug; 881():173206. PubMed ID: 32442539
[TBL] [Abstract][Full Text] [Related]
14. RAGE in diabetic nephropathy.
Yamamoto H; Watanabe T; Yamamoto Y; Yonekura H; Munesue S; Harashima A; Ooe K; Hossain S; Saito H; Murakami N
Curr Mol Med; 2007 Dec; 7(8):752-7. PubMed ID: 18331233
[TBL] [Abstract][Full Text] [Related]
15. Advanced glycation end products, oxidative stress and diabetic nephropathy.
Yamagishi S; Matsui T
Oxid Med Cell Longev; 2010; 3(2):101-8. PubMed ID: 20716934
[TBL] [Abstract][Full Text] [Related]
16. AGE/RAGE signaling-mediated endoplasmic reticulum stress and future prospects in non-coding RNA therapeutics for diabetic nephropathy.
Pathomthongtaweechai N; Chutipongtanate S
Biomed Pharmacother; 2020 Nov; 131():110655. PubMed ID: 32853909
[TBL] [Abstract][Full Text] [Related]
17. Receptor for advanced glycation endproducts (RAGE) and vascular inflammation: insights into the pathogenesis of macrovascular complications in diabetes.
Wendt T; Bucciarelli L; Qu W; Lu Y; Yan SF; Stern DM; Schmidt AM
Curr Atheroscler Rep; 2002 May; 4(3):228-37. PubMed ID: 11931721
[TBL] [Abstract][Full Text] [Related]
18. AGE/RAGE produces endothelial dysfunction in coronary arterioles in type 2 diabetic mice.
Gao X; Zhang H; Schmidt AM; Zhang C
Am J Physiol Heart Circ Physiol; 2008 Aug; 295(2):H491-8. PubMed ID: 18539754
[TBL] [Abstract][Full Text] [Related]
19. Salvianolic Acid A Protects Against Diabetic Nephropathy through Ameliorating Glomerular Endothelial Dysfunction via Inhibiting AGE-RAGE Signaling.
Hou B; Qiang G; Zhao Y; Yang X; Chen X; Yan Y; Wang X; Liu C; Zhang L; Du G
Cell Physiol Biochem; 2017; 44(6):2378-2394. PubMed ID: 29262395
[TBL] [Abstract][Full Text] [Related]
20. Modulatory role of HMG-CoA reductase inhibitors and ezetimibe on LDL-AGEs-induced ROS generation and RAGE-associated signalling in HEK-293 Cells.
Nabi R; Alvi SS; Shah A; Chaturvedi CP; Iqbal D; Ahmad S; Khan MS
Life Sci; 2019 Oct; 235():116823. PubMed ID: 31476307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
